



- (51) **International Patent Classification:**
C07D 277/30 (2006.01) *A61K 31/427* (2006.01)
A61K 31/426 (2006.01)
- (21) **International Application Number:**
PCT/US2015/025235
- (22) **International Filing Date:**
10 April 2015 (10.04.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/978,460 11 April 2014 (11.04.2014) US
- (71) **Applicant:** MEDIMMUNE LLC [US/US]; One MedImmune Way, Gaithersburg, MD 20878 (US).
- (72) **Inventors; and**
- (71) **Applicants :** GINGIPALLI, Lakshmaiah [US/US]; Astrazeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451 (US). TOADER, Dorin [US/US]; MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). WANG, Fengjiang [US/US]; c/o Astrazeneca Intellectual Property, Astrazeneca R&d Boston, 35 Gatehouse Drive, Waltham, MD 02451 (US).
- (74) **Agents:** BARRETT, Rebecca et al.; Astrazeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** TUBULYSIN DERIVATIVES

(57) **Abstract:** Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone or as drug conjugates with antibodies are provided. The tubulysin derivatives consist of a tetrapeptide scaffold comprising methyl and ethyl substituted piperidines. The tubulysin conjugates further comprise monoclonal antibody via succinimide linkers.

